CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Fludarabine +3 moredrug
Likely dose
Fludarabine 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00506129
NCT00506129Phase 2Completed
CompareCT.gov

Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL)

M.D. Anderson Cancer Center·interventional·Posted Jul 25, 2007·Updated Dec 29, 2020

In Brief

A Phase 2 clinical trial evaluating Fludarabine, Melphalan, and 2 other interventions for Lymphoma and Disorder Related to Bone Marrow Transplantation. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to see if receiving a transplant of blood stem cells (cells that can produce blood) or bone marrow from either a related donor (brother, sister or other relative) or an unrelated voluntary donor will help patients with advanced cutaneous T-cell lymphoma. The length of time that patients who receive the treatment remain free of disease will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Disorder Related to Bone Marrow Transplantation
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 25, 2007
Enrollment StartSep 1, 2003
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11.8 yearsPosted 18.9 years ago

Interventions

Fludarabinedrug

25 mg/m\^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.

Melphalandrug

70 mg/m\^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.

Allogeneic Transplantprocedure

Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.

Thymoglobulindrug

2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.